id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-033821-i14dmmps	Guo, Yue-Cheng	Antihepatic Fibrosis Drugs in Clinical Trials	2020-08-24		.txt	text/plain	5042	306	40	11 Treatment based on the etiology may not completely attenuate all fibrosis patients, as there are currently no effective managements for eliminating the cause of certain liver diseases, such as autoimmune hepatitis. In a multicenter, randomized, placebo-controlled trial, 19 patients with NASH exhibited improvements of liver histological features after treatment with OCA (25 mg, 72 weeks). Currently, two active phase II clinical trials (NCT03486912, NCT03486899) are investigating the efficacy and safety of pegbelfermin in patients with NASH-related fibrosis as determined by liver biopsy. A phase II clinical trial 51 showed that pirfenidone (1200 mg daily, 24 months) improved inflammation, fibrosis, and steatosis in patients with hepatitis C virusrelated cirrhosis. 52 A phase II clinical trial (NCT02499562) has explored the effective dose and safety of hydronidone capsules in patients with liver fibrosis induced by hepatitis B virus infection in Shanghai General Hospital, Shanghai, China.	./cache/cord-033821-i14dmmps.txt	./txt/cord-033821-i14dmmps.txt